KNSA

SEC source: 0001179110-20-001763 · edgar.xml · nonDerivative · entry 2

Paolini John F. · CIK 0001741533 · SVP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,000

F1 · kind: The Share Option exercise and sale of Class A Common Shares ("Shares") reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 16, 2019.

F3 · shares: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $18.26 to $18.44. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

SEC source: 0001179110-20-001763 · edgar.xml · nonDerivative · entry 1

Paolini John F. · CIK 0001741533 · SVP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,277

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The Share Option exercise and sale of Class A Common Shares ("Shares") reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 16, 2019.

SEC source: 0001179110-19-012840 · edgar.xml · derivative · entry 1

Rizvi Qasim · CIK 0001794636 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,337

Underlying: Class A Common Shares · 7,337 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Restricted Share Unit represents a contingent right to receive one Class A Common Share of the Issuer.

F2 · derivative.exercise_date: The Restricted Share Units will vest in a single installment on December 31, 2020, subject to the Reporting Person's continuous employment or service to the Issuer or any of its subsidiaries on the vesting date.

F2 · derivative.expiration_date: The Restricted Share Units will vest in a single installment on December 31, 2020, subject to the Reporting Person's continuous employment or service to the Issuer or any of its subsidiaries on the vesting date.

SEC source: 0001179110-19-012551 · edgar.xml · derivative · entry 1

Rizvi Qasim · CIK 0001794636 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Class A Common Shares · 30,000 shares

Expires 2029-12-05

F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in thirty-six equal monthly installments thereafter. The vesting commencement date is December 9, 2019.

SEC source: 0001179110-19-012550 · edgar.xml · derivative · entry 2

Paolini John F. · CIK 0001741533 · SVP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 209,574

Underlying: Class A Common Shares · 8,000 shares

Expires 2026-09-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The option vested and became exercisable as to 25% of the total grant of 227,574 Class A Common Shares on the first anniversary of the vesting commencement date and vests in equal monthly installments over a three-year period thereafter. The vesting commencement date is August 15, 2016.

SEC source: 0001179110-19-012550 · edgar.xml · nonDerivative · entry 1

Paolini John F. · CIK 0001741533 · SVP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001179110-19-010889 · edgar.xml · derivative · entry 2

Paolini John F. · CIK 0001741533 · SVP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 217,574

Underlying: Class A Common Shares · 10,000 shares

Expires 2026-09-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The option vested and became exercisable as to 25% of the total grant of 227,574 Class A Common Shares on the first anniversary of the vesting commencement date and vests in equal monthly installments over a three-year period thereafter. The vesting commencement date is August 15, 2016.

SEC source: 0001179110-19-010889 · edgar.xml · nonDerivative · entry 1

Paolini John F. · CIK 0001741533 · SVP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001179110-19-010488 · edgar.xml · derivative · entry 1

Patel Sanj K · CIK 0001532218 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 190,000

Underlying: Class A Common Shares · 190,000 shares

Expires 2029-09-16

F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in thirty-six equal monthly installments thereafter. The vesting commencement date is September 17, 2019.

SEC source: 0001179110-19-010490 · edgar.xml · derivative · entry 1

Mahoney Stephen F. · CIK 0001741389 · President & COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 82,000

Underlying: Class A Common Shares · 82,000 shares

Expires 2029-09-16

F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in thirty-six equal monthly installments thereafter. The vesting commencement date is September 17, 2019.

SEC source: 0001179110-19-010489 · edgar.xml · derivative · entry 1

Beetham Thomas W. · CIK 0001741382 · EVP & Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,000

Underlying: Class A Common Shares · 45,000 shares

Expires 2029-09-16

F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in thirty-six equal monthly installments thereafter. The vesting commencement date is September 17, 2019.

SEC source: 0001179110-19-010487 · edgar.xml · derivative · entry 1

Heberlig Chris · CIK 0001532217 · EVP & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Class A Common Shares · 50,000 shares

Expires 2029-09-16

F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in thirty-six equal monthly installments thereafter. The vesting commencement date is September 17, 2019.

SEC source: 0001179110-19-010486 · edgar.xml · derivative · entry 1

Paolini John F. · CIK 0001741533 · SVP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,000

Underlying: Class A Common Shares · 46,000 shares

Expires 2029-09-16

F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in thirty-six equal monthly installments thereafter. The vesting commencement date is September 17, 2019.

SEC source: 0001179110-20-001565 · edgar.xml · nonDerivative · entry 2

Patel Sanj K · CIK 0001532218 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · Held by The Anglia 2013 Revocable Trust, u/d/t August 15, 2013

Disclosed balance after: 245,685

F1 · shares: The Reporting Person transferred all Class A Common Shares and all Class B Common Shares held by the Reporting Person to a family trust, of which the Reporting Person is trustee, on August 7, 2019 and July 31, 2019, respectively. The Reporting Person is the sole beneficiary of the trust.

SEC source: 0001179110-20-001565 · edgar.xml · nonDerivative · entry 1

Patel Sanj K · CIK 0001532218 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · shares: The Reporting Person transferred all Class A Common Shares and all Class B Common Shares held by the Reporting Person to a family trust, of which the Reporting Person is trustee, on August 7, 2019 and July 31, 2019, respectively. The Reporting Person is the sole beneficiary of the trust.

SEC source: 0001179110-20-001565 · edgar.xml · derivative · entry 5

Patel Sanj K · CIK 0001532218 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · Held by The Anglia 2013 Revocable Trust, u/d/t August 15, 2013

Disclosed balance after: 1,526,160

Underlying: Class A Common Shares · 1,526,160 shares

Expires not disclosed

F3 · derivative.exercise_price: Each Class B Common Share is convertible at any time at the election of the holder, subject to certain contractual arrangements entered into between the Reporting Person and the Issuer, into one Class A Common Share or one Class B1 Common Share and will automatically convert into Class A Common Shares upon transfer to an unaffiliated party.

F1 · shares: The Reporting Person transferred all Class A Common Shares and all Class B Common Shares held by the Reporting Person to a family trust, of which the Reporting Person is trustee, on August 7, 2019 and July 31, 2019, respectively. The Reporting Person is the sole beneficiary of the trust.

F3 · derivative.exercise_date: Each Class B Common Share is convertible at any time at the election of the holder, subject to certain contractual arrangements entered into between the Reporting Person and the Issuer, into one Class A Common Share or one Class B1 Common Share and will automatically convert into Class A Common Shares upon transfer to an unaffiliated party.

F4 · derivative.exercise_date: In accordance with certain contractual arrangements entered into between the Reporting Person and the Issuer, the Anglia 2013 Revocable Trust, u/d/t August 15, 2013 is not entitled to convert the Class B Common Shares into Class A Common Shares, if immediately following such conversion, the Reporting Person would beneficially own more than 4.99% of the Issuer's issued and outstanding Class A Common Shares, unless the Reporting Person provides the Issuer with 61-days' prior written notice of such conversion.

F3 · derivative.expiration_date: Each Class B Common Share is convertible at any time at the election of the holder, subject to certain contractual arrangements entered into between the Reporting Person and the Issuer, into one Class A Common Share or one Class B1 Common Share and will automatically convert into Class A Common Shares upon transfer to an unaffiliated party.

F4 · balance_after: In accordance with certain contractual arrangements entered into between the Reporting Person and the Issuer, the Anglia 2013 Revocable Trust, u/d/t August 15, 2013 is not entitled to convert the Class B Common Shares into Class A Common Shares, if immediately following such conversion, the Reporting Person would beneficially own more than 4.99% of the Issuer's issued and outstanding Class A Common Shares, unless the Reporting Person provides the Issuer with 61-days' prior written notice of such conversion.

SEC source: 0001179110-20-001565 · edgar.xml · derivative · entry 4

Patel Sanj K · CIK 0001532218 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Shares · 1,526,160 shares

Expires not disclosed

F3 · derivative.exercise_price: Each Class B Common Share is convertible at any time at the election of the holder, subject to certain contractual arrangements entered into between the Reporting Person and the Issuer, into one Class A Common Share or one Class B1 Common Share and will automatically convert into Class A Common Shares upon transfer to an unaffiliated party.

F1 · shares: The Reporting Person transferred all Class A Common Shares and all Class B Common Shares held by the Reporting Person to a family trust, of which the Reporting Person is trustee, on August 7, 2019 and July 31, 2019, respectively. The Reporting Person is the sole beneficiary of the trust.

F3 · derivative.exercise_date: Each Class B Common Share is convertible at any time at the election of the holder, subject to certain contractual arrangements entered into between the Reporting Person and the Issuer, into one Class A Common Share or one Class B1 Common Share and will automatically convert into Class A Common Shares upon transfer to an unaffiliated party.

F4 · derivative.exercise_date: In accordance with certain contractual arrangements entered into between the Reporting Person and the Issuer, the Anglia 2013 Revocable Trust, u/d/t August 15, 2013 is not entitled to convert the Class B Common Shares into Class A Common Shares, if immediately following such conversion, the Reporting Person would beneficially own more than 4.99% of the Issuer's issued and outstanding Class A Common Shares, unless the Reporting Person provides the Issuer with 61-days' prior written notice of such conversion.

F3 · derivative.expiration_date: Each Class B Common Share is convertible at any time at the election of the holder, subject to certain contractual arrangements entered into between the Reporting Person and the Issuer, into one Class A Common Share or one Class B1 Common Share and will automatically convert into Class A Common Shares upon transfer to an unaffiliated party.

SEC source: 0001638599-19-000600 · doc4_6145.xml · nonDerivative · entry 4

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,840

F2 · kind: Represents Common Shares distributed by 667, L.P. ("667", and together Life Sciences, the "Funds") as part of an in-kind pro rata distribution without consideration in accordance with pecuniary interest to Julian C. Baker, Felix J. Baker and other investors in 667.

F2 · price: Represents Common Shares distributed by 667, L.P. ("667", and together Life Sciences, the "Funds") as part of an in-kind pro rata distribution without consideration in accordance with pecuniary interest to Julian C. Baker, Felix J. Baker and other investors in 667.

F5 · balance_after: Common Shares held directly by Julian C. Baker received from the in-kind pro rata distribution without consideration reported above.

SEC source: 0001638599-19-000600 · doc4_6145.xml · nonDerivative · entry 3

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,840

F2 · kind: Represents Common Shares distributed by 667, L.P. ("667", and together Life Sciences, the "Funds") as part of an in-kind pro rata distribution without consideration in accordance with pecuniary interest to Julian C. Baker, Felix J. Baker and other investors in 667.

F2 · price: Represents Common Shares distributed by 667, L.P. ("667", and together Life Sciences, the "Funds") as part of an in-kind pro rata distribution without consideration in accordance with pecuniary interest to Julian C. Baker, Felix J. Baker and other investors in 667.

F4 · balance_after: Common Shares held directly by Felix J. Baker received from the in-kind pro rata distribution without consideration reported above.

SEC source: 0001638599-19-000600 · doc4_6145.xml · nonDerivative · entry 2

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 98,980

F2 · kind: Represents Common Shares distributed by 667, L.P. ("667", and together Life Sciences, the "Funds") as part of an in-kind pro rata distribution without consideration in accordance with pecuniary interest to Julian C. Baker, Felix J. Baker and other investors in 667.

F2 · price: Represents Common Shares distributed by 667, L.P. ("667", and together Life Sciences, the "Funds") as part of an in-kind pro rata distribution without consideration in accordance with pecuniary interest to Julian C. Baker, Felix J. Baker and other investors in 667.

F3 · ownership.nature: After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Shares reported in column 5 of Table I directly held by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.

F6 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds.

F7 · ownership.nature: The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds. Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

SEC source: 0001179110-19-006868 · edgar.xml · derivative · entry 1

Malley Thomas · CIK 0001403322 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,760

Underlying: Class A Common Shares · 18,760 shares

Expires 2029-05-28

F1 · derivative.exercise_date: The option vests and becomes exercisable in twelve substantially equal monthly installments following the date of grant. The date of grant is May 29, 2019.

SEC source: 0001179110-19-006869 · edgar.xml · derivative · entry 1

Quart Barry D · CIK 0001384243 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,760

Underlying: Class A Common Shares · 18,760 shares

Expires 2029-05-28

F1 · derivative.exercise_date: The option vests and becomes exercisable in twelve substantially equal monthly installments following the date of grant. The date of grant is May 29, 2019.

SEC source: 0001179110-19-006867 · edgar.xml · derivative · entry 1

McCain Tracey L · CIK 0001683600 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,760

Underlying: Class A Common Shares · 18,760 shares

Expires 2029-05-28

F1 · derivative.exercise_date: The option vests and becomes exercisable in twelve substantially equal monthly installments following the date of grant. The date of grant is May 29, 2019.

SEC source: 0001179110-19-006866 · edgar.xml · derivative · entry 1

Popovits Kimberly J · CIK 0001333482 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,760

Underlying: Class A Common Shares · 18,760 shares

Expires 2029-05-28

F1 · derivative.exercise_date: The option vests and becomes exercisable in twelve substantially equal monthly installments following the date of grant. The date of grant is May 29, 2019.

SEC source: 0001638599-19-000562 · doc4_6129.xml · derivative · entry 2

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 37,520

Underlying: Class A Common Shares · 37,520 shares

Expires 2029-05-29

F1 · derivative.exercise_price: 18,760 non-qualified stock options ("Stock Options") exercisable solely into Class A common shares ("Class A Common Shares") of Kiniksa Pharmaceuticals, Ltd. (the "Issuer") each granted to Felix J. Baker, a managing member of Baker Bros. Advisors (GP) LLC (the "Adviser GP") and Dr. Stephen R. Biggar, a full time employee of Baker Bros. Advisors LP (the "Adviser") on May 29, 2019, pursuant to the Issuer's 2018 Incentive Award Plan. The Stock Options with a strike price of $15.47 vest in 12 equal monthly installments and expire 10 years from the date of grant. Felix J. Baker and Dr. Biggar serve on the board of directors of the Issuer (the "Board") as representatives of 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds").

F1 · derivative.exercise_date: 18,760 non-qualified stock options ("Stock Options") exercisable solely into Class A common shares ("Class A Common Shares") of Kiniksa Pharmaceuticals, Ltd. (the "Issuer") each granted to Felix J. Baker, a managing member of Baker Bros. Advisors (GP) LLC (the "Adviser GP") and Dr. Stephen R. Biggar, a full time employee of Baker Bros. Advisors LP (the "Adviser") on May 29, 2019, pursuant to the Issuer's 2018 Incentive Award Plan. The Stock Options with a strike price of $15.47 vest in 12 equal monthly installments and expire 10 years from the date of grant. Felix J. Baker and Dr. Biggar serve on the board of directors of the Issuer (the "Board") as representatives of 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds").

F1 · derivative.expiration_date: 18,760 non-qualified stock options ("Stock Options") exercisable solely into Class A common shares ("Class A Common Shares") of Kiniksa Pharmaceuticals, Ltd. (the "Issuer") each granted to Felix J. Baker, a managing member of Baker Bros. Advisors (GP) LLC (the "Adviser GP") and Dr. Stephen R. Biggar, a full time employee of Baker Bros. Advisors LP (the "Adviser") on May 29, 2019, pursuant to the Issuer's 2018 Incentive Award Plan. The Stock Options with a strike price of $15.47 vest in 12 equal monthly installments and expire 10 years from the date of grant. Felix J. Baker and Dr. Biggar serve on the board of directors of the Issuer (the "Board") as representatives of 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds").

F1 · ownership.nature: 18,760 non-qualified stock options ("Stock Options") exercisable solely into Class A common shares ("Class A Common Shares") of Kiniksa Pharmaceuticals, Ltd. (the "Issuer") each granted to Felix J. Baker, a managing member of Baker Bros. Advisors (GP) LLC (the "Adviser GP") and Dr. Stephen R. Biggar, a full time employee of Baker Bros. Advisors LP (the "Adviser") on May 29, 2019, pursuant to the Issuer's 2018 Incentive Award Plan. The Stock Options with a strike price of $15.47 vest in 12 equal monthly installments and expire 10 years from the date of grant. Felix J. Baker and Dr. Biggar serve on the board of directors of the Issuer (the "Board") as representatives of 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds").

F2 · ownership.nature: Pursuant to the policies of the Adviser, Felix J. Baker and Dr. Biggar do not have a right to any of the Issuer's securities issued as part of their service on the Board and the Funds are entitled to receive all the pecuniary interest in the securities issued. The Funds each own an indirect proportionate pecuniary interest in the Stock Options. Solely as a result of Felix J. Baker's and Julian C. Baker's ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the Stock Options (i.e. no direct pecuniary interest).

F4 · ownership.nature: The Adviser serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. The Adviser GP is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds.

F5 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose. Pursuant to agreements between Felix J. Baker, Dr. Biggar and the Adviser, the Adviser has investment and dispositive power over the stock options of the Issuer and any Class A Common Shares received as a result of the exercise of stock options.

F6 · ownership.nature: After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital L.P. and (ii) Life Sciences, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in Stock Options beneficially owned by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.

F7 · ownership.nature: The disclosure of the grant of Stock Options reported on this form is a single grant to each of the recipients noted in footnote 1 totaling 37,520 Stock Options. The 37,520 Stock Options are reported for each of the Funds as each has an indirect pecuniary interest.

SEC source: 0001638599-19-000562 · doc4_6129.xml · derivative · entry 1

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 37,520

Underlying: Class A Common Shares · 37,520 shares

Expires 2029-05-29

F1 · derivative.exercise_price: 18,760 non-qualified stock options ("Stock Options") exercisable solely into Class A common shares ("Class A Common Shares") of Kiniksa Pharmaceuticals, Ltd. (the "Issuer") each granted to Felix J. Baker, a managing member of Baker Bros. Advisors (GP) LLC (the "Adviser GP") and Dr. Stephen R. Biggar, a full time employee of Baker Bros. Advisors LP (the "Adviser") on May 29, 2019, pursuant to the Issuer's 2018 Incentive Award Plan. The Stock Options with a strike price of $15.47 vest in 12 equal monthly installments and expire 10 years from the date of grant. Felix J. Baker and Dr. Biggar serve on the board of directors of the Issuer (the "Board") as representatives of 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds").

F1 · derivative.exercise_date: 18,760 non-qualified stock options ("Stock Options") exercisable solely into Class A common shares ("Class A Common Shares") of Kiniksa Pharmaceuticals, Ltd. (the "Issuer") each granted to Felix J. Baker, a managing member of Baker Bros. Advisors (GP) LLC (the "Adviser GP") and Dr. Stephen R. Biggar, a full time employee of Baker Bros. Advisors LP (the "Adviser") on May 29, 2019, pursuant to the Issuer's 2018 Incentive Award Plan. The Stock Options with a strike price of $15.47 vest in 12 equal monthly installments and expire 10 years from the date of grant. Felix J. Baker and Dr. Biggar serve on the board of directors of the Issuer (the "Board") as representatives of 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds").

F1 · derivative.expiration_date: 18,760 non-qualified stock options ("Stock Options") exercisable solely into Class A common shares ("Class A Common Shares") of Kiniksa Pharmaceuticals, Ltd. (the "Issuer") each granted to Felix J. Baker, a managing member of Baker Bros. Advisors (GP) LLC (the "Adviser GP") and Dr. Stephen R. Biggar, a full time employee of Baker Bros. Advisors LP (the "Adviser") on May 29, 2019, pursuant to the Issuer's 2018 Incentive Award Plan. The Stock Options with a strike price of $15.47 vest in 12 equal monthly installments and expire 10 years from the date of grant. Felix J. Baker and Dr. Biggar serve on the board of directors of the Issuer (the "Board") as representatives of 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds").

F1 · ownership.nature: 18,760 non-qualified stock options ("Stock Options") exercisable solely into Class A common shares ("Class A Common Shares") of Kiniksa Pharmaceuticals, Ltd. (the "Issuer") each granted to Felix J. Baker, a managing member of Baker Bros. Advisors (GP) LLC (the "Adviser GP") and Dr. Stephen R. Biggar, a full time employee of Baker Bros. Advisors LP (the "Adviser") on May 29, 2019, pursuant to the Issuer's 2018 Incentive Award Plan. The Stock Options with a strike price of $15.47 vest in 12 equal monthly installments and expire 10 years from the date of grant. Felix J. Baker and Dr. Biggar serve on the board of directors of the Issuer (the "Board") as representatives of 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds").

F2 · ownership.nature: Pursuant to the policies of the Adviser, Felix J. Baker and Dr. Biggar do not have a right to any of the Issuer's securities issued as part of their service on the Board and the Funds are entitled to receive all the pecuniary interest in the securities issued. The Funds each own an indirect proportionate pecuniary interest in the Stock Options. Solely as a result of Felix J. Baker's and Julian C. Baker's ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the Stock Options (i.e. no direct pecuniary interest).

F3 · ownership.nature: After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in Stock Options beneficially owned by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.

F4 · ownership.nature: The Adviser serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. The Adviser GP is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds.

F5 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose. Pursuant to agreements between Felix J. Baker, Dr. Biggar and the Adviser, the Adviser has investment and dispositive power over the stock options of the Issuer and any Class A Common Shares received as a result of the exercise of stock options.

F7 · ownership.nature: The disclosure of the grant of Stock Options reported on this form is a single grant to each of the recipients noted in footnote 1 totaling 37,520 Stock Options. The 37,520 Stock Options are reported for each of the Funds as each has an indirect pecuniary interest.

SEC source: 0001104659-19-013177 · a4.xml · derivative · entry 1

Heberlig Chris · CIK 0001532217 · EVP & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,000

Underlying: Class A Common Shares · 46,000 shares

Expires 2029-03-03

F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in thirty-six equal monthly installments thereafter. The vesting commencement date is March 4, 2019.

SEC source: 0001104659-19-013176 · a4.xml · derivative · entry 1

Mahoney Stephen F. · CIK 0001741389 · President & COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 83,000

Underlying: Class A Common Shares · 83,000 shares

Expires 2029-03-03

F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in thirty-six equal monthly installments thereafter. The vesting commencement date is March 4, 2019.

SEC source: 0001104659-19-013175 · a4.xml · derivative · entry 1

Paolini John F. · CIK 0001741533 · SVP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,000

Underlying: Class A Common Shares · 51,000 shares

Expires 2029-03-03

F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in thirty-six equal monthly installments thereafter. The vesting commencement date is March 4, 2019.

SEC source: 0001104659-19-013174 · a4.xml · derivative · entry 1

Patel Sanj K · CIK 0001532218 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 187,000

Underlying: Class A Common Shares · 187,000 shares

Expires 2029-03-03

F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in thirty-six equal monthly installments thereafter. The vesting commencement date is March 4, 2019.

SEC source: 0001104659-19-013173 · a4.xml · derivative · entry 1

Beetham Thomas W. · CIK 0001741382 · EVP & Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,000

Underlying: Class A Common Shares · 42,000 shares

Expires 2029-03-03

F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in thirty-six equal monthly installments thereafter. The vesting commencement date is March 4, 2019.

SEC source: 0001104659-19-013172 · a4.xml · derivative · entry 1

Levy Richard S · CIK 0001454983 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,965

Underlying: Class A Common Shares · 37,965 shares

Expires 2029-03-03

F1 · derivative.exercise_date: The option vests and becomes exercisable as to one third of the total grant on the first anniversary of the vesting commencement date and vests in equal monthly installments over a twenty-four month period thereafter. The vesting commencement date is March 4, 2019.

SEC source: 0001638599-19-000191 · doc4_5926.xml · derivative · entry 2

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 8,837,349

Underlying: Class A Common Shares · 1,818,475 shares

Expires not disclosed

F3 · derivative.exercise_price: Represents the Issuer's Class A1 common shares which are subject to a beneficial ownership limitation, convertible at the election of the holder on a 1 for 1 basis into Class A common shares. The Class A1 common shares have no expiration date. Each Class A1 common share automatically converts into one Class A common share upon transfer, except for transfers to or between affiliated holders.

F2 · price: Pursuant to Instruction 4(c)(iii), this response has been left blank.

F3 · derivative.exercise_date: Represents the Issuer's Class A1 common shares which are subject to a beneficial ownership limitation, convertible at the election of the holder on a 1 for 1 basis into Class A common shares. The Class A1 common shares have no expiration date. Each Class A1 common share automatically converts into one Class A common share upon transfer, except for transfers to or between affiliated holders.

F3 · derivative.expiration_date: Represents the Issuer's Class A1 common shares which are subject to a beneficial ownership limitation, convertible at the election of the holder on a 1 for 1 basis into Class A common shares. The Class A1 common shares have no expiration date. Each Class A1 common share automatically converts into one Class A common share upon transfer, except for transfers to or between affiliated holders.

F3 · derivative.underlying: Represents the Issuer's Class A1 common shares which are subject to a beneficial ownership limitation, convertible at the election of the holder on a 1 for 1 basis into Class A common shares. The Class A1 common shares have no expiration date. Each Class A1 common share automatically converts into one Class A common share upon transfer, except for transfers to or between affiliated holders.

F1 · ownership.nature: 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences" and together with 667, the "Funds") purchased 181,525 and 1,818,475 Class A common shares of Kiniksa Pharmaceuticals, Ltd. (the "Issuer"), respectively, for $18.26 per share pursuant to a private placement with the Issuer that closed on February 4, 2019.

F4 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the Investment Adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are principals of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds.

F5 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F7 · ownership.nature: After giving effect to the transactions reported herein, and as a result of their ownership interest in Baker Brothers Life Sciences Capital (GP), LLC, Julian C. Baker and Felix J. Baker may be deemed to have an indirect pecuniary interest in the Issuer's securities reported in column 9 of Table II directly held by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.

SEC source: 0001638599-19-000191 · doc4_5926.xml · derivative · entry 1

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 916,043

Underlying: Class A Common Shares · 181,525 shares

Expires not disclosed

F3 · derivative.exercise_price: Represents the Issuer's Class A1 common shares which are subject to a beneficial ownership limitation, convertible at the election of the holder on a 1 for 1 basis into Class A common shares. The Class A1 common shares have no expiration date. Each Class A1 common share automatically converts into one Class A common share upon transfer, except for transfers to or between affiliated holders.

F2 · price: Pursuant to Instruction 4(c)(iii), this response has been left blank.

F3 · derivative.exercise_date: Represents the Issuer's Class A1 common shares which are subject to a beneficial ownership limitation, convertible at the election of the holder on a 1 for 1 basis into Class A common shares. The Class A1 common shares have no expiration date. Each Class A1 common share automatically converts into one Class A common share upon transfer, except for transfers to or between affiliated holders.

F3 · derivative.expiration_date: Represents the Issuer's Class A1 common shares which are subject to a beneficial ownership limitation, convertible at the election of the holder on a 1 for 1 basis into Class A common shares. The Class A1 common shares have no expiration date. Each Class A1 common share automatically converts into one Class A common share upon transfer, except for transfers to or between affiliated holders.

F3 · derivative.underlying: Represents the Issuer's Class A1 common shares which are subject to a beneficial ownership limitation, convertible at the election of the holder on a 1 for 1 basis into Class A common shares. The Class A1 common shares have no expiration date. Each Class A1 common share automatically converts into one Class A common share upon transfer, except for transfers to or between affiliated holders.

F1 · ownership.nature: 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences" and together with 667, the "Funds") purchased 181,525 and 1,818,475 Class A common shares of Kiniksa Pharmaceuticals, Ltd. (the "Issuer"), respectively, for $18.26 per share pursuant to a private placement with the Issuer that closed on February 4, 2019.

F4 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the Investment Adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are principals of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds.

F5 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F6 · ownership.nature: After giving effect to the transactions reported herein, and as a result of their ownership interest in Baker Biotech Capital (GP), LLC, Julian C. Baker and Felix J. Baker may be deemed to have an indirect pecuniary interest in securities reported in column 9 of Table II directly held by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.

SEC source: 0001104659-18-058111 · a4.xml · derivative · entry 1

Patel Sanj K · CIK 0001532218 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 125,000

Underlying: Class A Common Shares · 125,000 shares

Expires 2028-09-19

F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in equal monthly installments over a three-year period thereafter. The vesting commencement date is September 20, 2018.

SEC source: 0001104659-18-058110 · a4.xml · derivative · entry 1

Paolini John F. · CIK 0001741533 · SVP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,000

Underlying: Class A Common Shares · 45,000 shares

Expires 2028-09-19

F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in equal monthly installments over a three-year period thereafter. The vesting commencement date is September 20, 2018.

SEC source: 0001104659-18-058108 · a4.xml · derivative · entry 1

Heberlig Chris · CIK 0001532217 · EVP & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,000

Underlying: Class A Common Shares · 45,000 shares

Expires 2028-09-19

F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in equal monthly installments over a three-year period thereafter. The vesting commencement date is September 20, 2018.

SEC source: 0001104659-18-058109 · a4.xml · derivative · entry 1

Mahoney Stephen F. · CIK 0001741389 · President & COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Class A Common Shares · 50,000 shares

Expires 2028-09-19

F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in equal monthly installments over a three-year period thereafter. The vesting commencement date is September 20, 2018.

SEC source: 0001104659-18-058107 · a4.xml · derivative · entry 1

Beetham Thomas W. · CIK 0001741382 · EVP & Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,000

Underlying: Class A Common Shares · 45,000 shares

Expires 2028-09-19

F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in equal monthly installments over a three-year period thereafter. The vesting commencement date is September 20, 2018.

SEC source: 0001104659-18-036488 · a4.xml · derivative · entry 7

Patel Sanj K · CIK 0001532218 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,526,160

Underlying: Class A Common Shares · 428,203 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each share of Class B Common Shares is convertible at any time at the election of the holder, subject to certain contractual arrangements entered into between the Reporting Person and the Issuer, into one share of Class A Common Shares or one share of Class B1 Common Shares and will automatically convert into Class A Common Shares upon transfer to an unaffiliated party.

F4 · derivative.exercise_date: Each share of Class B Common Shares is convertible at any time at the election of the holder, subject to certain contractual arrangements entered into between the Reporting Person and the Issuer, into one share of Class A Common Shares or one share of Class B1 Common Shares and will automatically convert into Class A Common Shares upon transfer to an unaffiliated party.

F4 · derivative.expiration_date: Each share of Class B Common Shares is convertible at any time at the election of the holder, subject to certain contractual arrangements entered into between the Reporting Person and the Issuer, into one share of Class A Common Shares or one share of Class B1 Common Shares and will automatically convert into Class A Common Shares upon transfer to an unaffiliated party.

SEC source: 0001104659-18-036488 · a4.xml · derivative · entry 6

Patel Sanj K · CIK 0001532218 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Shares · 63,922 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Upon closing of the Issuer's initial public offering, the preferred shares automatically converted into the Issuer's Class A Common Shares on a one-for-one basis.

F1 · derivative.exercise_date: Upon closing of the Issuer's initial public offering, the preferred shares automatically converted into the Issuer's Class A Common Shares on a one-for-one basis.

F1 · derivative.expiration_date: Upon closing of the Issuer's initial public offering, the preferred shares automatically converted into the Issuer's Class A Common Shares on a one-for-one basis.

SEC source: 0001104659-18-036488 · a4.xml · derivative · entry 5

Patel Sanj K · CIK 0001532218 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Shares · 71,967 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Upon closing of the Issuer's initial public offering, the preferred shares automatically converted into the Issuer's Class A Common Shares on a one-for-one basis.

F1 · derivative.exercise_date: Upon closing of the Issuer's initial public offering, the preferred shares automatically converted into the Issuer's Class A Common Shares on a one-for-one basis.

F1 · derivative.expiration_date: Upon closing of the Issuer's initial public offering, the preferred shares automatically converted into the Issuer's Class A Common Shares on a one-for-one basis.

SEC source: 0001104659-18-036488 · a4.xml · derivative · entry 4

Patel Sanj K · CIK 0001532218 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Class B Common Shares · 428,203 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Upon closing of the Issuer's initial public offering, the preferred shares automatically converted into the Issuer's Class B Common Shares on a one-for-one basis.

F3 · derivative.exercise_date: Upon closing of the Issuer's initial public offering, the preferred shares automatically converted into the Issuer's Class B Common Shares on a one-for-one basis.

F3 · derivative.expiration_date: Upon closing of the Issuer's initial public offering, the preferred shares automatically converted into the Issuer's Class B Common Shares on a one-for-one basis.

SEC source: 0001104659-18-036488 · a4.xml · nonDerivative · entry 1

Patel Sanj K · CIK 0001532218 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 245,685

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001104659-18-036487 · a4.xml · derivative · entry 5

Beetham Thomas W. · CIK 0001741382 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 414,157

Underlying: Class A Common Shares · 48,172 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each share of Class B Common Shares is convertible at any time at the election of the holder into one share of Class A Common Shares or one share of Class B1 Common Shares and will automatically convert into Class A Common Shares upon transfer to an unaffiliated party.

F4 · derivative.exercise_date: Each share of Class B Common Shares is convertible at any time at the election of the holder into one share of Class A Common Shares or one share of Class B1 Common Shares and will automatically convert into Class A Common Shares upon transfer to an unaffiliated party.

F4 · derivative.expiration_date: Each share of Class B Common Shares is convertible at any time at the election of the holder into one share of Class A Common Shares or one share of Class B1 Common Shares and will automatically convert into Class A Common Shares upon transfer to an unaffiliated party.

SEC source: 0001104659-18-036487 · a4.xml · derivative · entry 4

Beetham Thomas W. · CIK 0001741382 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Shares · 6,392 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Upon closing of the Issuer's initial public offering, the preferred shares automatically converted into the Issuer's Class A Common Shares on a one-for-one basis.

F1 · derivative.exercise_date: Upon closing of the Issuer's initial public offering, the preferred shares automatically converted into the Issuer's Class A Common Shares on a one-for-one basis.

F1 · derivative.expiration_date: Upon closing of the Issuer's initial public offering, the preferred shares automatically converted into the Issuer's Class A Common Shares on a one-for-one basis.

SEC source: 0001104659-18-036487 · a4.xml · derivative · entry 3

Beetham Thomas W. · CIK 0001741382 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Class B Common Shares · 48,172 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Upon closing of the Issuer's initial public offering, the preferred shares automatically converted into the Issuer's Class B Common Shares on a one-for-one basis.

F3 · derivative.exercise_date: Upon closing of the Issuer's initial public offering, the preferred shares automatically converted into the Issuer's Class B Common Shares on a one-for-one basis.

F3 · derivative.expiration_date: Upon closing of the Issuer's initial public offering, the preferred shares automatically converted into the Issuer's Class B Common Shares on a one-for-one basis.

SEC source: 0001104659-18-036487 · a4.xml · nonDerivative · entry 1

Beetham Thomas W. · CIK 0001741382 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 79,589

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001104659-18-036486 · a4.xml · derivative · entry 2

Malley Thomas · CIK 0001403322 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Class A Common Shares · 71,967 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Upon closing of the Issuer's initial public offering, the preferred shares automatically converted into the Issuer's Class A Common Shares on a one-for-one basis.

F2 · derivative.exercise_date: Upon closing of the Issuer's initial public offering, the preferred shares automatically converted into the Issuer's Class A Common Shares on a one-for-one basis.

F2 · derivative.expiration_date: Upon closing of the Issuer's initial public offering, the preferred shares automatically converted into the Issuer's Class A Common Shares on a one-for-one basis.

F1 · ownership.nature: Mr. Malley is the president of Mossrock Capital, LLC ("Mossrock") and may be deemed to beneficially own the shares owned by Mossrock.

SEC source: 0001104659-18-036486 · a4.xml · nonDerivative · entry 1

Malley Thomas · CIK 0001403322 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 71,967

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · ownership.nature: Mr. Malley is the president of Mossrock Capital, LLC ("Mossrock") and may be deemed to beneficially own the shares owned by Mossrock.